Veozah (Fezolinetant): A Non-Hormonal Option for Hot Flashes

Veozah (fezolinetant) is a prescription pill and the first non-hormonal medication approved by the FDA specifically to treat moderate-to-severe vasomotor symptoms — the medical term for hot flashes and night sweats — caused by menopause. It was approved in 2023 and offers a genuinely new option for women who cannot or prefer not to use estrogen.

For decades, the most effective treatment for hot flashes was hormone therapy (HRT), which replaces declining estrogen. But HRT is not suitable for everyone — some women have medical reasons to avoid estrogen, such as a history of certain breast cancers or blood clots, and others simply prefer a non-hormonal route. Until recently, their options were limited to off-label antidepressants and lifestyle measures with modest effects.

Veozah changed that by targeting the brain mechanism behind hot flashes directly, without using hormones. It is taken as one 45 mg tablet once a day, with or without food. It is part of a new drug class called NK3 receptor antagonists, and a second drug in the broader category, elinzanetant (Lynkuet), has followed it. Together they represent the biggest shift in non-hormonal menopause care in a generation. For a comparison of the newer option, see our guide to [Lynkuet (elinzanetant)](/blog/lynkuet-elinzanetant-non-hormonal-hot-flash-treatment).

Veozah works by blocking the NK3 receptor in a part of the brain called the hypothalamus, which acts as your body's thermostat. This resets the temperature-control system that menopause throws off balance — without using any hormones.

Here is the mechanism in plain terms. Deep in the brain are nerve cells called KNDy neurons that help regulate body temperature. Estrogen normally keeps these neurons in check. As estrogen falls during menopause, these neurons become overactive and enlarged, and they over-stimulate the brain's heat-control center through a signaling molecule called neurokinin B. The result is that your thermostat becomes hypersensitive and triggers a hot flash — flushing, sweating, and heat — in response to tiny temperature changes that would normally go unnoticed.

Fezolinetant blocks the NK3 receptor that neurokinin B uses to send those signals. By interrupting this overactive pathway, it calms the brain's thermostat and reduces both how often and how intensely hot flashes occur. Because it targets the temperature mechanism rather than replacing estrogen, it sidesteps the hormone-related concerns that make HRT unsuitable for some women. This is a fundamentally different approach from anything previously available, and understanding it helps explain why Veozah can work even for women who must strictly avoid estrogen. To understand the underlying biology of why hot flashes happen, our explainer on [why hot flashes happen](/blog/menopause-hot-flashes-why-they-happen-and-what-helps) gives the full picture.

Veozah works well for many women, cutting the frequency of moderate-to-severe hot flashes by roughly 2.5 per day on average and significantly reducing their severity, based on the SKYLIGHT 1 and SKYLIGHT 2 trials. These were large phase 3 studies that together included about 2,800 postmenopausal women with frequent hot flashes.

In those trials, women taking the 45 mg dose saw statistically and clinically meaningful reductions in both how often and how severe their hot flashes were at 4 and 12 weeks compared with placebo. Importantly, the benefit began quickly — many women noticed fewer hot flashes within the first week of treatment — and improvements were maintained over 52 weeks of follow-up, showing the effect holds up long term.

It is worth setting realistic expectations. Veozah reduces hot flashes substantially but does not eliminate them for everyone, and a reduction of about 2.5 per day represents an average, meaning some women respond more strongly and others less. Hormone therapy generally produces a somewhat larger reduction in hot flashes for women who can take it, so Veozah is often described as a highly effective option particularly valuable for those who cannot use estrogen. For the right person, the difference in daily comfort, sleep, and quality of life can be dramatic. If night-time symptoms are your main struggle, the improved sleep that comes with fewer night sweats is often the most welcome benefit; see our guide on [menopause night sweats](/blog/menopause-night-sweats-causes-treatments-stop).

Veozah is best for women with moderate-to-severe menopausal hot flashes who cannot or prefer not to take estrogen — including some breast cancer survivors, women with a history of blood clots, and those who simply want a non-hormonal option. It is a prescription medication, so suitability is decided with a provider.

The most common side effects reported in trials were generally mild to moderate and included headache, fatigue, abdominal pain, diarrhea, and back pain. Most women tolerate it well. The most important safety consideration is the liver: fezolinetant can cause elevated liver enzymes, so the FDA requires liver-function blood tests before starting and periodically during the first months of treatment. Women with known liver problems or certain kidney conditions may not be candidates, and it should not be combined with certain other medications that affect the same liver pathway.

Because it is non-hormonal, Veozah does not carry the estrogen-related risks that some women must avoid, which is its central advantage. However, it also does not provide the other benefits of estrogen therapy, such as protection for bones and relief of vaginal symptoms — so women needing those may still discuss HRT or additional treatments. The decision comes down to your symptoms, your medical history, and your preferences. A provider who is knowledgeable about menopause can help you weigh Veozah against [bioidentical and synthetic HRT](/blog/bioidentical-vs-synthetic-hrt-truth-about-difference) and other non-hormonal approaches to find the best fit.

Veozah differs from HRT and older non-hormonal options by targeting the brain's temperature pathway directly without hormones, offering strong hot-flash relief for women who need an estrogen-free choice. Understanding how the options compare helps you have a focused conversation with your provider.

Hormone therapy remains the most effective treatment for hot flashes for women who can take it, and it adds bone protection and relief of vaginal symptoms. But it is not suitable for everyone. Older non-hormonal options include certain low-dose antidepressants (SSRIs and SNRIs), gabapentin, and the supplement and lifestyle approaches like [magnesium](/blog/magnesium-menopause-sleep-mood-bone-mineral) and cognitive behavioral therapy. These help some women but generally produce smaller reductions in hot flashes than Veozah or HRT.

The newest comparison is between Veozah and elinzanetant (Lynkuet), a related NK-receptor blocker. Elinzanetant targets two receptors (NK1 and NK3) and has shown benefits for sleep and mood in addition to hot flashes, while Veozah targets NK3 alone. Both are non-hormonal and effective; the right choice depends on your specific symptoms, other medications, and liver health. There has never been more choice in managing hot flashes without hormones. The best path is an individualized one: bring your symptoms, your history, and your preferences to a menopause-informed provider, and use the growing menu of options — hormonal and non-hormonal — to build relief that fits your life.